thrombocythemia


Also found in: Dictionary, Thesaurus, Medical.
Related to thrombocythemia: hydroxyurea, thrombocytosis

thrombocythemia

[¦thräm·bō‚sī′thē·mē·ə]
(medicine)
Mentioned in ?
References in periodicals archive ?
Polycythemia Vera-PV 95% JAK2 V617F 1% JAK2 exon 12 4% other Essential Thrombocythemia-ET 50-60% JAK2 20-25% CALR 5-10% MPL 5-25% other Primary Myelofibrosis -PMF 50-60% JAK2 20-30% CALR 5-10% MPL 0-25% other ET: essential thrombocythemia; PMF:primary myelofibrosis; PV: policytemia vera Note: Table made from pie chart.
Characteristics Myelofibrosis patients Controls Age, median (range) 66 (38-85) 36.5 (22-56) Gender (N) Male 3 1 Female 5 3 Diagnosis (N) PMF fibrotic phase 6 NA PMF pre-fibrotic 1 Post-ET MF 1 Dynamic international NA prognosis system (N) Low 2 Intermediate 1 4 Intermediate 2 2 High 0 Hemoglobin (g/dL), 13.3 (8.7-14.9) 14.6 (13.9-14.8) median (range) Leukocytes (cells/ 26,800 (8,060-103,000) 5,250 (4,980-5,370) [mm.sup.3]), median (range) Circulating blasts 0-2 0 (%), range Circulating CD34+ 59.5 (11.2-476) NA cells (/[mm.sup.3]), median (range) Platelets (cells/ 254,000 196,500 [mm.sup.3]), (165,000-381,000) (164,000-276,000) median (range) Chemotherapy at time of sample collection (N) None 6 NA Hydroxyurea 2 MF: myelofibrosis; PMF: primary myelofibrosis; ET: essential thrombocythemia.
Papilloedema with Peripapillary Haemorrhages in Severe Anaemia with Thrombocythemia
Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis.
A meta-analysis of clinical outcomes in essential thrombocythemia. Leukemia research 2009;33:67-73.
Wadenvik, "Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis," Leukemia & Lymphoma, vol.
Barbui, "Essential thrombocythemia treatment algorithm 2018," Blood Cancer Journal, vol.
analyzed patients with polycythemia vera (PV) and essential thrombocythemia (ET) and found increased numbers of circulating Tregs and an enrichment in highly suppressive subsets (defined as [CD39.sup.+]/HLA-DR+) in patients treated with PegIFN-[alpha] with respect to those treated with hydroxyurea [67].
Leukocytosis at diagnosis is associated with a higher risk of thrombosis and major hemorrhage in patients with polycythemia vera (PV) and essential thrombocythemia (ET).
A fetal blood sample showed increased anemia and thrombocythemia.
(6.) Barbui T, Carobbio A, Rambaldi A, Finazzi G (2009) Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor?